Laron syndrome patients show 0% diabetes and only 1 cancer case vs 5% and 17% in control groups over 22 years of study in Ecuador. The condition involves a growth hormone receptor mutation that prevents IGF-1 production, which researchers believe may prevent cancer cell survival.
Rare Genetic Disorder in Ecuador Offers Cancer Prevention Clues
Patients with Laron syndrome face social discrimination, limited access to expensive growth treatments ($2,400/month), and missed developmental windows for therapy.